Compare GSK plc (GSK) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Xylem, Inc. — how do they compare? GSK plc trades at $52.75 (market cap $101.34B), while Xylem, Inc. trades at $124.46 (market cap $28.86B). The key difference: GSK plc is far larger — about 3.5× Xylem, Inc.'s market cap, and GSK plc pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| GSK | XYL | |
|---|---|---|
Market Cap | $101.34B | $28.86B |
Sector | Health | Industrials |
52-Week High | $61.18 | $152.95 |
52-Week Low | $36.20 | $106.34 |
Enterprise Value | $121.95B | $30.12B |
Dividend Yield | 3.49% | 1.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Xylem (XYL) trades at $125.26, up 3.05% over 24 hours, with a bullish technical signal and consistent earnings beats. Revenue grew from $5.5B in 2022 to $9.0B in 2025, with net margins expanding to 10.59%. Recent news highlights partnerships, leadership appointments, and a dividend declaration, reinforcing its position in water technology solutions.
Outlook remains positive with a consensus price target of $152, implying 21% upside. Risks include execution challenges and macroeconomic pressures, but strong cash flow and analyst support suggest long-term growth potential for investors focused on sustainable infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
